TSOI — Therapeutic Solutions International Income Statement
0.000.00%
Last trade - 00:00
- $2.80m
- $3.47m
- $0.21m
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.003 | 0.028 | 0.063 | 0.146 | 0.207 |
Cost of Revenue | |||||
Gross Profit | 0.001 | 0.024 | 0.05 | 0.103 | 0.127 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 1.2 | 1.07 | 1.91 | 2.45 | 3.29 |
Operating Profit | -1.2 | -1.04 | -1.85 | -2.3 | -3.08 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1.87 | -1.7 | -2.2 | -2.96 | -3.68 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.87 | -1.7 | -2.2 | -2.96 | -3.68 |
Net Income Before Extraordinary Items | |||||
Net Income | -1.87 | -1.7 | -2.2 | -2.96 | -3.68 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.87 | -1.7 | -2.2 | -2.96 | -3.68 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.002 | -0.001 | -0.001 | -0.001 | -0.001 |